Nektar Therapeutics
NKTR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.5% | 6.8% | -64.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 72.7% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -248.6% | -302.3% | -391.7% | 59.9% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -301.3% | -372.2% | -486.4% | 24.9% |
| EPS Diluted | -1.87 | -2.95 | -3.62 | 0.51 |
| % Growth | 36.6% | 18.5% | -809.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |